View an enhanced version of our Annual Report.
View an enhanced version of our Proxy Statement.
You may request paper copies of the annual materials online now, by email or by phone by dialing
866-648-8133.
Your vote is Important!
Please be sure to vote your shares online now or vote by phone by dialing 866-229-2195.
Date:
July 10, 2025
Time:
11:30 AM PT
Location:
19800 MacArthur Blvd., Suite 250
Irvine, California 92612
About Us
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (“ALS”). The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential.